Disease characterized by the rapid swelling
POPULARITY
Podcast summary of articles from the March 2025 edition of the Journal of Emergency Medicine from the American Academy of Emergency Medicine. Topics include pediatric airways, IV contrast induced nephropathy, toxic mushrooms, TXA for ACEI angioedema, bias in patient surveys, and hyperbaric oxygen therapy. Guest speaker is Dr. Matthew Carvey.
In this month's episode of the HAE Speaks Podcast, please join Raffi Tachdjian, MD, MPH, Associate Clinical Professor, David Geffen School of Medicine at UCLA, and Kenny Robinson, MD, Head of Medical Affairs, North America at Pharvaris, for a discussion about the full spectrum of a bradykinin-mediated angioedema attack. This podcast episode highlights the experience of the physician and those living with bradykinin-mediated angioedema, explores the nuances of attack progression and resolution, and shares strategies to inform clinical assessment and improve outcomes for individuals with HAE.We would like to thank Pharvaris for sponsoring this episode of the HAE Speaks Podcast.
In this episode, we review the high-yield topic of Hereditary Angioedema from the Immunology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
JACI: In Practice Editor Robert Zeiger describes the March issue, the theme of which is “Cough”. Theme topics covered include the clinical approach to chronic cough, cough reflex hypersensitivity as a key treatable trait, nonpharmacological approaches to chronic cough, and cough-variant asthma. Dr. Zeiger then presents the Highlights of the Original Articles in the issue, which are on the topics of Cough, Angioedema, Asthma, Drug Allergy, Food Allergy, Inborn Errors of Immunity, Mast Cell Diseases, and Rhinitis and Sinusits.
Hereditary angioedema (HAE) is a rare condition often due to reduced levels C1-inhibitor, which is a protein involved in various physiological processes in plasma, most notably with the complement system. C1-inhibitor also binds and inhibits plasma kallikrein and factor XIa, thereby affecting bradykinin production. It is believed that the disruptions of these processes cause fluid to leak from the blood to connective tissue, leading to HAE attacks. Owing to its rarity, HAE is often poorly recognized, leading to misdiagnoses and significant diagnostic delays. Being aware of the early signs and symptoms of this condition can lead to faster diagnosis and the use of effective therapies.This program is supported by independent medical education grants from Takeda. To earn CME credit please visit https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-hereditary-angioedema/lessons/consider-rare-suspecting-and-diagnosing-hereditary-angioedema-module/ Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in primary care, pediatrics, emergency care, otolaryngology, gastroenterology, and dermatology .Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:- Describe the early symptoms of HAE and its clinical relevance.- Apply best practices to diagnose HAE more efficiently to reduce diagnostic delays. Faculty Jonathan A Bernstein, MDProfessor of MedicineUniversity of Cincinnati Department of Internal MedicineDivision of Immunology, Allergy SectionPartner Advanced Allergy Services, LLCPartner Bernstein Clinical Research Center Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Bernstein discloses the following relevant financial relationships with ineligible companies:Advisory Board Consultant: Takeda/Shire, CSL Behring, KalVista, Pharming, Biocryst, Ionis, Intellia, Pharvaris, Astria and BiomarinGrant/Research Support: Takeda/Shire, CSL Behring, KalVista, Pharming, Biocryst, Ionis, Intellia, Pharvaris, Astria and BiomariSpeaker's Bureau: PharmingPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
This educational program is made possible by an unrestricted grant from Takeda Pharmaceuticals.Hereditary angioedema (HAE) is a rare genetic disease that results in immunologic attacks that can be life-threatening. HAE is the result of reduced levels of C1-inhibitor, a protein involved in various physiological processes in plasma, most notably with the complement system. C1-inhibitor also binds and inhibits plasma kallikrein and factor XIa, thereby affecting bradykinin production. It is believed that the disruptions of these processes lead to fluid leaking from the blood to connective tissue which leads to HAE attacks. It is these HAE attacks that tend to put persons in the emergency department or unable to attend work or school.Numerous therapies are now available for patients with HAE to both treat acute attacks and prevent attacks via prophylactic treatment.With so many treatment options now available, is it disheartening to learn that not all patients with HAE are receiving equal care or access to care. Patients with HAE living in rural areas as patients from underrepresented racial or ethnic backgrounds are not provided the same level of care as patients, especially Caucasian patients, living in more affluent areas. This panel discussion by three clinical research leaders in HAE, Drs. Aleena Banerji, Timothy Craig, and Marc Riedl, provide an overview of the discrepancies in care observed in certain patient populations, as well as a discussion on best practices to reduce those inequalities moving forward.To view this program in video format, go to https://checkrare.com/improving-health-equity-in-hereditary-angioedema-hae-a-panel-discussion/
JACI: In Practice Editor Michael Schatz describes the December issue, the theme of which is “Adherence Considerations in Allergy/Immunology.” The theme review articles comprehensively cover many aspects of adherence in patients with allergic and immunologic diseases, including factors affecting adherence, strategies for improvement, special considerations in specific groups, and the use of technology to improve adherence. Dr. Schatz then presents the Highlights of the Original Articles in the issue, which are on the topics of Allergic Bronchopulmonary Aspergillosis, Anaphylaxis, Angioedema, Asthma, Drug Allergy, Eosinophilic Disorders, Food Allergy, and Rhinitis and Sinusitis.
ROMA (ITALPRESS) - In questa edizione:- Ovaio policistico, verso una nuova definizione per migliore diagnosi- Angioedema ereditario, un cortometraggio racconta la malattia- Arriva in Italia un nuovo farmaco contro la colite ulcerosamgg/mrv
VENEZIA (ITALPRESS) - Un racconto poetico per spiegare una patologia che pochi conoscono e che oggi, grazie alla ricerca, non fa più paura come un tempo: la malattia in questione si chiama angioedema ereditario, il cortometraggio che la racconta in un tenero viaggio tra generazioni si intitola "Il Colloquio" ed è stato presentato durante l'81^ Mostra del Cinema di Venezia.xa7/fsc/mrv
In this week's episode we'll discuss minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Then, we'll learn about IPSS-R downstaging before transplant in MDS. Finally we'll hear about the connection between hereditary angioedema and venous thromboembolism. Featured Articles:EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma Does IPSS-R down-staging before transplantation improve the prognosis of patients with Myelodysplastic Neoplasms? Increased risk of venous thromboembolism [or VTE] in young and middle-aged individuals with hereditary angioedema: a family study
Send us a Text Message.“HAE is a different disease than it was because of the advancement of treatments…make sure that you're offering the best form of therapy available to patients and their families.” -- Dr. Stephen BetschelJoin Dr. Mariam Hanna in an enlightening conversation with Dr. Stephen Betschel, an associate professor in the Department of Medicine and Clinical Immunologist and Allergist at St. Michael's Hospital, University Health Network. Dr. Betschel, a global authority on hereditary angioedema (HAE), shares his extensive knowledge on this rare and potentially life-threatening condition.On this episode:Understanding Hereditary Angioedema:Dr. Betschel provides a detailed explanation of HAE, an autosomal dominant condition characterized by C1 inhibitor deficiency. He discusses how this deficiency leads to the overproduction of bradykinin, causing swelling in various parts of the body, including the hands, feet, face, abdomen, and throat.Types and Diagnosis:Explore the different types of HAE (type 1, type 2, and hereditary angioedema normal) and the importance of accurate diagnosis. Dr. Betschel explains the diagnostic process, which includes measuring C4 and C1 inhibitor levels and function, and emphasizes the role of clinical and family history in identifying potential cases. Genetic testing can also be useful in certain cases.Clinical Manifestations and Triggers:Learn about the varying clinical manifestations of HAE, which can differ significantly even among patients in the same family. Dr. Betschel highlights common triggers for HAE attacks, such as infections, trauma, and spontaneous episodes, emphasizing the importance of understanding these triggers for effective management.Management and Treatment:Discover the latest advancements in HAE treatment, including on-demand therapies for acute attacks and long-term prophylaxis options. Dr. Betschel discusses medications such as Icatibant, intravenous and subcutaneous C1 inhibitors, and the promising future of oral treatments and gene therapy.Patient Care and Support:Dr. Betschel underscores the importance of providing comprehensive care and support for HAE patients. He advises healthcare providers to engage with patients actively, optimize attack control, and improve quality of life through personalized treatment plans.Tune in to this episode for an in-depth exploration of hereditary angioedema, offering valuable insights and practical advice for healthcare providers.Visit the Canadian Society of Allergy and Clinical ImmunologyFind an allergist using our helpful toolFind Dr. Hanna on X, previously Twitter, @PedsAllergyDoc or CSACI @CSACI_caThe Allergist is produced for CSACI by PodCraft Productions
On this episode Lara and Vyanka talk to Dr Hilary Longhurst all about Hereditary Angioedema and the exciting new treatments coming down the line. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter. Hosted on Acast. See acast.com/privacy for more information.
In this episode, Tracey Davidoff, MD and Joe Toscano, MD discuss the May 2024 Evidence-Based Urgent Care article, Evidence-Based Management of Angioedema in Urgent CareIntroduction to Angioedema ManagementUnderstanding AngioedemaDifferential Diagnosis and Clinical AssessmentTreatment Protocols for AngioedemaControversies and Cutting-Edge TreatmentsDisposition and Patient ManagementKey Points and Clinical PearlsConclusion and Wrap-Up
Can you recognize and treat life-threatening, nonallergic angioedema? Credit available for this activity expires: 3/8/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000342?ecd=bdc_podcast_libsyn_mscpedu
Angioedema is defined by upper airway swelling secondary to an immune response. The trigger and subsequent physiological response are how we categorize it. In this podcast, we discuss how to diagnose and treat both types: IgE/Histamine-mediated and Bradykinin-mediated. We also touch on how to address the difficult airway that may or may not lead to intubation. All in all, do not fear angioedema but respect it. Get CE hours for our podcast episodes HERE! -------------------------------------------- Twitter @heavyhelmet Facebook @heavyliesthehelmet Instagram @heavyliesthehelmet Website heavyliesthehelmet.com Email contact@heavyliesthehelmet.com Disclaimer: The views, information, or opinions expressed on the Heavy Lies the Helmet podcast are solely those of the individuals involved and do not necessarily represent those of their employers and their employees. Heavy Lies the Helmet, LLC is not responsible for the accuracy of any information available for listening on this platform. The primary purpose of this series is to educate and inform, but it is not a substitute for your local laws, medical direction, or sound judgment. -------------------------------------------- Crystals VIP by From The Dust | https://soundcloud.com/ftdmusic Music promoted by https://www.free-stock-music.com
“I think CARE will grow and grow.” Dr Thomas Buttgereit joins Professor Marcus Maurer to discuss the recently launched Chronic Angioedema Registry (CARE), including benefits for patients, current capabilities and how to get involved. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Utilise the following external links and access additional resources relating to the topics discussed in this episode: Chronic Angioedema Registry. Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
This 25-minute CME-accredited program, hosted by Aleena Banerji, MD, Associate Professor at Harvard Medical School and Clinical Director of the Massachusetts General Hospital ( MGH) Allergy and Immunology Unit, highlights the current treatment options for patients with hereditary angioedema (HAE). Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from Ionis Pharmaceuticals Inc. Estimated time to complete: 0.50 hours Start date: January 31, 2024 End date: January 30, 2025To obtain CME credit, go to https://checkrare.com/learning/p-hereditary-angioedema-current-treatment-options/Activity Faculty Aleena Banerji, MD Associate Professor Clinical Director, MGH Allergy and Immunology Unit Harvard Medical School Massachusetts General Hospital Boston, MA Target Audience This activity has been designed to meet the educational needs of physicians specializing in allergy medicine, immunology, internal medicine, and pediatrics who may be involved in the care for individuals with HAE. Other healthcare providers (HCPs) may also participate. Learning Objectives After participating in the activity, learners should be better able to • Review current guidelines and unmet needs of patients with HAE Accreditation and Credit Designation In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians American Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPs Other members of the care team will receive a certificate of participation. Disclosure Statement According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows: Faculty Educator Dr. Banerji discloses the following relevant financial relationships with ineligible companies: • Research Grant: Takeda, Ionis Pharmaceuticals, Astria • Advisory Board: Takeda, BioCryst, Astria, Intellia, CSL Behring, KalVista, ADARx Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Method of Participation There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments at https://checkrare.com/learning/p-hereditary-angioedema-current-treatment-options/ Your certificate will be emailed to you in within 30 days. Privacy For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ Contact For any questions, please contact: CEServices@academycme.org Copyright © 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
Maybe it's steroids? Maybe she's born with it? Wait… no, she's definitely born with it. It's HAE. How fitting is it that Rare Disease Day falls on a fairly rare day, Feburary 29th! In this episode, the fellas sit down with Jordyn Campbell, who not only shares her eye-opening journey with hereditary angioedema (HAE) but also how she's punching back with advocacy and awareness. What the hell is HAE? Here's the elevator pitch - your body decides to puff up like a balloon at the most inconvenient times, thanks to a rare genetic curveball. Welcome to Jordyn's world, where getting swole is just part of the daily routine, no gym membership needed. But there's more to her story than just coping with HAE. Through battles with misdiagnoses and the quest for the right treatment, Jordyn highlights the brighter side of her condition, including her impactful work with HAE Canada and finding unexpected joys in life's challenges. To cap it all off in the wrap-up, the boys are diving into a cheeky discussion about a recent study from plastic surgeons on the ideal male buttocks. Thankfully the Gen-Z consultant came high key came through to translate the science with a zero dose of cringe. The TLDR; This deep dive into male booty aesthetics fills a big ol' gap in the glow-up science, giving us the 411 on what's peak for the peach. These gems could pave the way for next-level booty sculpting moves, making sure bros walking into the OR can walk out feeling 100.Stick around for the end of the show to hear Jordyn's latest single “Hit and Run”Key Takeaways- Hereditary angioedema (HAE) is a rare genetic condition characterized by severe swelling of various body parts.- Receiving a diagnosis for HAE can be challenging, with many individuals experiencing misdiagnosis or a lack of clear answers.- Living with HAE can have a significant impact on daily life, including work, relationships, and sexual activity.- Advocacy and raising awareness are crucial for individuals with HAE to receive proper care and support.- The availability and coverage of different medications for HAE vary from province to province, leading to variations in treatment for patients.- Finding the right drug for HAE patients can be complex, as different drugs work differently for each individual based on their gene mutation.- The decision to have children when living with a hereditary condition like HAE involves considering the potential impact on the child's life and the parents' preparedness to handle the challenges.- Genetic testing can provide valuable information for individuals considering having children, allowing them to make informed decisions about their family planning.- HAE has not taken anything away from Jordyn's life, and she sees it as a part of her normalcy. It has given her confidence, the ability to help others, and a platform to share her experiences.- Having a hereditary condition like HAE can shape one's perspective on life and provide a unique understanding and preparedness for the challenges it presents.Follow Sickboy:Instagram: https://www.instagram.com/sickboypodcastTiktok: https://www.tiktok.com/@sickboypodcastDiscord: https://discord.gg/expeUDNSupport Sickboy:Patreon - https://www.patreon.com/sickboy
Maybe it's steroids? Maybe she's born with it? Wait… no, she's definitely born with it. It's HAE. How fitting is it that Rare Disease Day falls on a fairly rare day, Feburary 29th! In this episode, the fellas sit down with Jordyn Campbell, who not only shares her eye-opening journey with hereditary angioedema (HAE) but also how she's punching back with advocacy and awareness. What the hell is HAE? Here's the elevator pitch - your body decides to puff up like a balloon at the most inconvenient times, thanks to a rare genetic curveball. Welcome to Jordyn's world, where getting swole is just part of the daily routine, no gym membership needed. But there's more to her story than just coping with HAE. Through battles with misdiagnoses and the quest for the right treatment, Jordyn highlights the brighter side of her condition, including her impactful work with HAE Canada and finding unexpected joys in life's challenges. To cap it all off in the wrap-up, the boys are diving into a cheeky discussion about a recent study from plastic surgeons on the ideal male buttocks. Thankfully the Gen-Z consultant came high key came through to translate the science with a zero dose of cringe. The TLDR; This deep dive into male booty aesthetics fills a big ol' gap in the glow-up science, giving us the 411 on what's peak for the peach. These gems could pave the way for next-level booty sculpting moves, making sure bros walking into the OR can walk out feeling 100.Stick around for the end of the show to hear Jordyn's latest single “Hit and Run”Key Takeaways- Hereditary angioedema (HAE) is a rare genetic condition characterized by severe swelling of various body parts.- Receiving a diagnosis for HAE can be challenging, with many individuals experiencing misdiagnosis or a lack of clear answers.- Living with HAE can have a significant impact on daily life, including work, relationships, and sexual activity.- Advocacy and raising awareness are crucial for individuals with HAE to receive proper care and support.- The availability and coverage of different medications for HAE vary from province to province, leading to variations in treatment for patients.- Finding the right drug for HAE patients can be complex, as different drugs work differently for each individual based on their gene mutation.- The decision to have children when living with a hereditary condition like HAE involves considering the potential impact on the child's life and the parents' preparedness to handle the challenges.- Genetic testing can provide valuable information for individuals considering having children, allowing them to make informed decisions about their family planning.- HAE has not taken anything away from Jordyn's life, and she sees it as a part of her normalcy. It has given her confidence, the ability to help others, and a platform to share her experiences.- Having a hereditary condition like HAE can shape one's perspective on life and provide a unique understanding and preparedness for the challenges it presents.Follow Sickboy:Instagram: https://www.instagram.com/sickboypodcastTiktok: https://www.tiktok.com/@sickboypodcastDiscord: https://discord.gg/expeUDNSupport Sickboy:Patreon - https://www.patreon.com/sickboy
In this week's episode we'll report on the findings from a study evaluating the long-term outcomes of pulmonary embolism in children and adolescents, discuss a new mechanism for hereditary angioedema caused by a methionine-379 to lysine substitution in kininogens, and learn more about predictors of unsustained minimal residual disease negativity in multiple myeloma patients.
This 40-minute CME-accredited program, hosted by Aleena Banerji, MD, Associate Professor at Harvard Medical School and Clinical Director of the Massachusetts General Hospital ( MGH) Allergy and Immunology Unit, highlights the current and future treatment options for patients with hereditary angioedema (HAE). Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from Ionis Pharmaceuticals Inc. Estimated time to complete: 0.75 hours Start date: January 31, 2024 End date: January 30, 2025To obtain CME credit, go to https://checkrare.com/learning/p-hereditary-angioedema-current-and-future-treatment-options/ Activity Faculty Aleena Banerji, MD Associate Professor Clinical Director, MGH Allergy and Immunology Unit Harvard Medical School Massachusetts General Hospital Boston, MA Target Audience This activity has been designed to meet the educational needs of physicians specializing in allergy medicine, immunology, internal medicine, and pediatrics who may be involved in the care for individuals with HAE. Other healthcare providers (HCPs) may also participate. Learning Objectives After participating in the activity, learners should be better able to • Review current guidelines and unmet needs of patients with HAE • Understand clinical data of treatments in development for HAE Accreditation and Credit Designation In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians American Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPs Other members of the care team will receive a certificate of participation. Disclosure Statement According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows: Faculty Educator Dr. Banerji discloses the following relevant financial relationships with ineligible companies: • Research Grant: Takeda, Ionis Pharmaceuticals, Astria • Advisory Board: Takeda, BioCryst, Astria, Intellia, CSL Behring, KalVista, ADARx Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Method of Participation There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments at https://checkrare.com/learning/p-hereditary-angioedema-current-and-future-treatment-options/ Your certificate will be emailed to you in within 30 days. Privacy For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ Contact For any questions, please contact: CEServices@academycme.org Copyright © 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
MCHD District Chief April Currie joins the podcast crew to discuss an angioedema case that repeatedly left more questions than answers. Dr. Patrick was tasked with managing the airway and definitely has some lessons learned to share with the listeners.
Redes Sociales: Instagram Facebook Twitter (X) --- Send in a voice message: https://podcasters.spotify.com/pod/show/geniofm/message
Take Home Points: Airway management is paramount; expect a challenging intubation and consider controlling the airway early if there is apparent airway compromise. Understanding the cause of angioedema (mast cell vs. bradykinin mediated) helps dictate directed management. Urticaria and pruritus = MAST CELL mediated, which is treated like a standard allergic reaction. REBEL Core Cast ... Read more The post REBEL Core Cast 108.0 – Angioedema appeared first on REBEL EM - Emergency Medicine Blog.
Professor Marcus Maurer is joined by Professor Paula Busse to explore the multifaceted burdens of angioedema for patients and physicians. They discuss issues surrounding timely diagnosis, interpreting ambiguous symptoms, patient concerns about medications, and enhancing quality of life monitoring. Utilise the following external links to access additional resources relating to the topics discussed in this episode: Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema, The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update and the CARE Registry. Access additional resources by signing up to Medthority and to be notified for future 'All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry
Dr Régis de Albuquerque Campos joins Professor Marcus Maurer to discuss the implications of angioedema and its impact on people living with chronic spontaneous urticaria (CSU). Dr Campos highlights diverse aspects of the burden of CSU and the impact misdiagnosis has on quality of life. Professor Maurer provides an overview of the current treatment landscape, differential diagnosis, unmet needs in angioedema clinical trials and the utilisation of omalizumab in managing angioedema associated with CSU. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Utilise the following external links to access additional resources relating to the topics discussed in this episode: A Comprehensive Review of Bradykinin-Induced Angioedema Versus Histamine-Induced Angioedema in the Emergency Department, Isolated angioedema: A review of classification and update on management and The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update. Access additional resources by signing up to Medthority and to be notified for future 'All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry
TODAY ON THE ROBERT SCOTT BELL SHOW: Childhood mortality causality, Derrick Broze, The Conscious Resistance Network, Pyramid of Power docuseries, The technocratic state, Pfizer and Moderna plead ignorance, Heather Alice Shea, Atmana Academy, Intuitive Life Coaching, Spirituality and science, Prostate cancer options, Angioedema concerns and MORE! http://www.robertscottbell.com/natural-remedies/childhood-mortality-causality-derrick-broze-the-conscious-resistance-network-pyramid-of-power-docuseries-the-technocratic-state-pfizer-and-moderna-plead-ignorance-heather-alice-shea-atmana-acad/
Professor Markus Magerl joins Professor Marcus Maurer in this episode to explore the significance of differential diagnosis in the identification of angioedema in chronic spontaneous urticaria (CSU). Professor Magerl takes a deep dive into the prospective use of artificial intelligence (AI) in the analysis of data derived from a questionnaire utilising algorithmic models. Both professors, Maurer and Magerl, discuss the implications AI can have in enhancing the diagnostic accuracy of angioedema. Utilise the following external links to access additional resources relating to the topics discussed in this episode: 10 Questions - Using AI for diagnosing your or your patient´s angioedema, Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin‑Mediated vs. Mast Cell–Mediated Angioedema and Case Report: Recurrent Angioedema: Diagnosing the Rare and the Frequent. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Access additional resources by signing up to Medthority and to be notified for future 'All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry
Sorena Kiani, MBPhD, FRCP, FRCPath - Androgen Risk Reduction in Hereditary Angioedema: Why and How to Switch to Targeted Prophylactic Therapy?
Professor Marcus Maurer is accompanied by Professor Marc Riedl to delve into the symptomatology and pathophysiology of angioedema in chronic spontaneous urticaria (CSU). The mechanistic aetiology of angioedema within the context of CSU pathology is also explored. Professor Marc Riedl examines therapeutic treatments for patients concurrently experiencing angioedema in CSU while exploring how the characterisation of autoimmune and auto allergic pathophysiological mechanisms can impact treatment decisions. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. For more information on all UCARE activities please visit: https://ga2len-ucare.com/ and utilise the following external links to access additional resources relating to the topics discussed in this episode: Angioedema - Ten Questions, Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell–Mediated Angioedema, WAO/EAACI guideline for HAE, The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria, and Consensus on treatment goals in hereditary angioedema. For more information about the UCARE/ACARE network and its activities please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry
Contributor: Aaron Lessen, MD Educational Pearls: What is thrombolysis? Thrombolysis is performed by administration of a medication that promotes the body's natural ability to break up clots. These medications include Alteplase (tPA) and Tenecteplase (TNK). The main side effect of using such an agent is bleeding which typically occurs at puncture sites but can also occur internally. However, an unusual side effect of thrombolytic agents, which occurs in about 1-5% of cases, is angioedema. What is angioedema? Angioedema is a medical condition that causes swelling beneath the surface of the skin, typically in the face, lips, and throat (orolingual angioedema). Fluid leaks from blood vessels and accumulates in the deeper layers of the skin. How are these two connected? The mechanism by which angioedema occurs after thrombolysis is not well understood, but it is likely connected to how tPA can increase levels of bradykinin and histamine. Swelling can appear suddenly but can also occur up to 24 hours after thrombolysis, and may last for a few hours or several days. In some cases, angioedema can affect the airways, leading to difficulty breathing. What can be done? If this side effect occurs the provider can stop the medication or infusion and treat the patient with anti-histamines, steroids, epinephrine, and airway monitoring. Medications such as Berinert or Icatibant, typically used in hereditary angioedema or ACE-i-induced angioedema, can also be used but have limited evidence for their efficacy. Fun fact tPA-related angioedema is about 4 times more likely in patients on ACE inhibitors. This is likely related to how ACE inhibitors also increase bradykinin and histamine in a patient's body. References Zhu A, Rajendram P, Tseng E, Coutts SB, Yu AYX. Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review. Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12795. doi: 10.1002/rth2.12795. PMID: 36186106; PMCID: PMC9487449. Pahs L, Droege C, Kneale H, Pancioli A. A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration. Ann Emerg Med. 2016 Sep;68(3):345-8. doi: 10.1016/j.annemergmed.2016.02.019. Epub 2016 May 10. PMID: 27174372. Burd M, McPheeters C, Scherrer LA. Orolingual Angioedema After Tissue Plasminogen Activator Administration in Patients Taking Angiotensin-Converting Enzyme Inhibitors. Adv Emerg Nurs J. 2019 Jul/Sep;41(3):204-214. doi: 10.1097/TME.0000000000000250. PMID: 31356244. Sczepanski M, Bozyk P. Institutional Incidence of Severe tPA-Induced Angioedema in Ischemic Cerebral Vascular Accidents. Crit Care Res Pract. 2018 Sep 27;2018:9360918. doi: 10.1155/2018/9360918. PMID: 30363665; PMCID: PMC6180929. Summarized by Jeffrey Olson, MS1 | Edited by Meg Joyce & Jorge Chalit, OMS1
Sometimes during a medical event, a team can make all the correct choices and still lose a patient. In this episode, a patient experiencing angioedema presents our team with choices that are all undeniably fraught and filled with risk. As they relive the event, they discuss how they cope when things don't work out as they hoped, how they try to use the experience for future cases, and the importance of the support and communication of your colleagues. The AMPED team is joined by: Joan Noelker, MD, MACM, FACEP (pronouns: she/her/hers) Associate Vice Chair of Education for Emergency Medicine Washington University School of Medicine Nichole Ojala BSN, RN, CEN, CCRN Click here to download this episode today! As always thanks for listening and fly safe! Hawnwan Moy MD FACEP FAEMS John Wilmas MD FACEP FAEMS Joseph Hill RN BSN CMTE CFRN
$5 Q-BANK: https://www.patreon.com/highyieldfamilymedicine Intro 0:30, Asthma 1:29, COPD 7:50, Pulmonary function tests 13:03, Interstitial lung disease 16:23, Pneumonia 21:09, Tuberculosis 27:55, Fungal lung infections 32:03, Bronchiolitis 34:14, Acute bronchitis 35:14, Stridor 36:06, Croup 36:57, Foreign body aspiration 37:30, Epiglottits 39:38, Anaphylaxis 40:12, Angioedema 41:40, Nasopharyngeal obstructions 42:39, Lung cancer 45:05, Pulmonary embolism 47:43, Pneumothorax 51:00, Pleural effusion 54:09, Congestive heart failure and pulmonary edema 57:20, Non-cardiogenic pulmonary edema 1:01:38, Pulmonary hypertension 1:05:07, Honorable mentions 1:08:04, Practice questions, 01:10:42
The JournalFeed podcast for the week of Feb 6 to 10, 2023.These are summaries from just 2 of the 5 article we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.Zinc Vs. COVID Spoon FeedZinc supplementation for patients with COVID-19 decreased 30-day ICU admission rate and led to shorter symptom duration. Subgroup analysis showed these effects were especially pronounced for elderly patients and those with comorbid conditions.Tubing in Angioedema Spoon FeedIn patients presenting with angioedema, history of hypertension, shortness of breath, drooling, and anterior tongue or pharyngeal swelling were risk factors for eventual need for intubation.
Being given a whole new body might sound like something from a sci-fi movie - but a New Zealander says a new genetic treatment has felt just like that. Hereditary angioedema is a rare immune deficiency that causes random, disabling and potentially lethal swelling. It's estimated one in 50,000 people are living with the disorder. But in Auckland, a world-first clinical trial has so far eradicated symptoms for the ten participants. Niva Chittock reports.
Professor Marcus Maurer is joined by Professor Asli Gelincik as they discuss recurrent angioedema in chronic spontaneous urticaria, and treatment options which are currently available to alleviate this pathology. The mechanistic actions of mast cell-mediated angioedema and bradykinin-mediated angioedema are discussed and their implications are analysed.
Have you heard about "holistic" before? If you do, what do you think of it? Tune in because in this episode we will learn a story of a woman who had been diagnosed with a skin condition and tried her best to heal herself by going through with the conventional medicine. Unsatisfied with the results, she kept searching for someone who can help her on her health until finally she discovered Hygieia Wellness Clinic. Despite her unfamiliarity with natural methods of healing, she believe in it and disciplined herself to follow through Dr. Sowmya's advice from changing the diet, taking natural medicines instead of the ones on the pharmacy and as months gone by, she started seeing results until finally her health condition had gone. Listen and get inspired by her story! 01:53 - 06:07 - Mandana's background 06:04 - 14:53 - Mandana's pregnancy and how her PUPPP rush started 14:53 - 16:51 - Things Mandana did to heal and her view on the holistic healing process 16:47 - 19:47 -How long it took for the hives until it started going away 19:44 - 26:19 - What is the healing journey like for Mandana 26:14 - 42:35 - What gave her the courage and strength to not resort back on the unnatural way of healing 42:32 - 46:50 - Mandana's advice for those whose starting out to do the natural healing ways SOCIAL MEDIA PAGES : ➤ Facebook: https://www.facebook.com/hygieiaclinic ➤ Instagram: https://www.instagram.com/hygieiaclinic/ ➤ Pinterest: https://www.pinterest.ca/drs0881/ ➤ YouTube: https://www.youtube.com/channel/UC2BCblFP2Of-4n3ps79_-DA MENTIONED: ANGIOEDEMA PUPPP RUSH HOLISTIC AYURVEDA HIVES Naturopathic Medicine Course FOR MORE INFORMATION, VISIT OUR WEBSITE: ➤ Website: https://www.hygieiawellnessclinic.com/ CONTACT US: ➤ Email: info@hygieiahomeopathy.com ➤ Tel: (1)469-403-1999
In this episode, we review the high-yield topic of Hereditary Angioedema from the Dermatology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets
In this episode, Sam Ashoo, MD, interviews Prayag Mehta, MD, and Nikola Milanko, MD, two of the authors of the October 2022 Emergency Medicine Practice article on Angioedema in the Emergency Department Pathophysiology: Non-pitting edema of respiratory or GI tractHistamine meditated, bradykinin mediated, or idiopathicAcquired, inherited, or idiopathicDo they present differently? (Urticaria, speed of onset)Histamine MediatedMost common form: 40%-70%Can be triggered by NSAIDsCan be induced by physical mechanism like cold, vibrationIs rash a reliable method of distinguishing the types?Bradykinin MediatedMay progress slowlyCan be inherited or acquiredCommon triggers include ACE inhibitors and TPATable 1 Differential Diagnosis Prehospital CareProtect airwayEpi, steroids, antihistaminesAvoid CPAPED HistoryFigure 2: Distinguishing characteristics of histamine vs bradykinin mediatedED ExamImportance of repetitive examsAirway examinationLaryngoscopy?DiagnosticsFigure 6: Flow diagram of ED workupLabsImagingTreatmentAirway: IntubationMedicationSpecial PopulationsPediatricPregnant/lactating patientsControversiesTXADisposition
Dr. Ben Sandefur, Emergency Medicine attending at Mayo Clinic, joins Alex and Venk on the podcast to talk about angioedema and awake tracheal intubation. He reviews the different types of angioedema in a format designed to assist the emergency department practitioner with decision making and prognostication. This is followed by a description of how to prepare for and lead a team and patient through awake tracheal intubation using fiberoptic and video laryngoscopy techniques. Contacts TWITTER - @AlwaysOnEM; @VenkBellamkonda INSTAGRAM – @AlwaysOnEM; @Venk_like_vancomycin; @ASFinch EMAIL - AlwaysOnEM@gmail.com References Rosenbaum S, Wilkerson RG, Winters ME, Vilke GM, Wu MYC. Clinical Practice Statement: What is the Emergency Department Management of Patients with Angioedema Secondary to an ACE-Inhibitor? J Emerg Med. 2021 Jul;61(1):105-112 [from the American Academy of Emergency Medicine] https://pubmed.ncbi.nlm.nih.gov/34006418/ Moellman JJ, Bernstein JA, et al. A consensus parameter for the evaluation and management of angioedema in the emergency department. Acad Emerg Med. 2014 Apr;21(4):469-84 [from the American College of Allergy, Asthma & Immunology (ACAAI) and the Society for Academic Emergency Medicine (SAEM)] https://pubmed.ncbi.nlm.nih.gov/24730413/ Carrillo-Martin I, Gonzalez-Estrada A, Funni SA, Sandefur BJ, Jeffery MM, Campbell RL. Angioedema - related emergency department visits in the United States: Epidemiology and time trends, 2006-2015. J Allergy Clin Immunol Pract. 2020 Jul-Aug;8(7):2442-2444. https://pubmed.ncbi.nlm.nih.gov/32302784/ Ishoo E, Shah UK, Grillone GA, Stram JR, Fuleihan NS. Predicting airway risk in angioedema: staging system based on presentation. Otolaryngol Head Neck Surg. 1999 Sep;121(3):263-8 https://pubmed.ncbi.nlm.nih.gov/10471868/ Arthur J, Caro D, Topp S, Chadwick S, Driver B, Henson M, Norse A, Spencer H, Godwin SA, Guirgis F. Clinical predictors of endotracheal intubation in patients presenting to the emergency department with angioedema. Am J Emerg Med. 2022 Oct 19;63:44-49 https://pubmed.ncbi.nlm.nih.gov/36327748/ Sandefur BJ, Liu XW, Kaji AH, Campbell RL, Driver BE, Walls RM, Carlson JN, Brown CA. Emergency Department Intubations in Patients with Angioedema: A Report from the National Emergency Airway Registry. J Emerg Med. 2021 Nov;61(5):481-488 https://pubmed.ncbi.nlm.nih.gov/34479750/ Sandefur BJ, Oliveira Silva L, Lohse CM, Goyal KA, Barbara DW, Castaneda-Guarderas A, Liu XW, Campbell RL. Clinical features and outcomes associated with angioedema in the emergency department. West J Emerg Med. 2019 Aug 6;20(5):760-769 https://pubmed.ncbi.nlm.nih.gov/31539333/ Additional Resources Wilkerson RG, Moellman JJ. Hereditary Angioedema. Emerg Med Clin North Am. 2022 Feb;40(1):99-118 https://pubmed.ncbi.nlm.nih.gov/34782094/ Wilkerson RG, Winters ME. Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema. Emerg Med Clin North Am. 2022 Feb;40(1):79-98 https://pubmed.ncbi.nlm.nih.gov/34782093/
Bendita metilpredinosolona aceponato. El interior de mis muslos ha dejado de arder, aunque me toca empezar una batería completa de prueba alérgicas, por la repetición de episodios de angioedema.
Hello listener and welcome to episode 130 of the MPR Weekly Dose Podcast. This week we have news of the FDA's vote on an ALS treatment; CPAP and BiPAP device recalls; Orphan Drug designation for a novel CRISPR therapy; Imfinzi gains new approval; and Spevigo is approved for pustular psoriasis flares.
Show notes and links: https://www.chrisbeatcancer.com/how-joe-cross-ju…y-back-to-health/
In this episode we discuss the types of angioedema, clues to help differentiate them on history, and the management of patients with a diagnosis of hereditary angioedema. Written by: Dr. Maggie Jiang (Internal Medicine Resident) Reviewed by: Dr. Stephen Betschel (Clinical Immunology and Allergy) and Dr. Laura Walker (General Internal Medicine)
This is an overview and discussion on airway management in patients with angioedema. Dr. Doherty, Dr. Wachs, and Will Appleby discuss in detail thoughts on airway management in these patients.
This is a discussion with Dr. Doherty, Dr. Wachs, and Will on clinical pearls and treatment on patients with angioedema.
Welcome to Episode 14 of “The 2 View,” the podcast for EM and urgent care nurse practitioners and physician assistants! Show Notes for Episode 14 of “The 2 View” – Urticaria, Foreign Bodies, and a Special Interview Urticaria Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. Published 2014. Accessed February 11, 2022. https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Urticaria-2014.pdf Radecki RP, MS. Does New IV Urticaria Medication Offer Benefits Over Current Treatments? ACEP Now. Published June 15, 2021. Accessed February 11, 2022. https://www.acepnow.com/article/does-new-iv-urticaria-medication-offer-benefits-over-current-treatments/ Safety of use of high dose antihistamines in difficult-to-control chronic urticaria patients. J Am Acad Dermatol. Published May 1, 2015. Accessed February 11, 2022. https://www.jaad.org/article/S0190-9622(15)00371-0/fulltext Sarti L, Barni S, Giovannini M, Liccioli G, Novembre E, Mori F. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. Wiley Online Library. Published August 3, 2020. Accessed February 11, 2022. https://onlinelibrary.wiley.com/doi/10.1111/pai.13325 Schaefer P. Acute and Chronic Urticaria: Evaluation and Treatment. Am Fam Physician. Published June 2017. Accessed February 11, 2022. https://www.aafp.org/afp/2017/0601/p717.html Winters M. Clinical Practice Guideline: Initial Evaluation and Management of Patients Presenting with Acute Urticaria or Angioedema. AAEM - American Academy of Emergency Medicine. Published July 10, 2006. Accessed February 11, 2022. https://www.aaem.org/resources/statements/position/clinical-practice-guideline-initial-evaluation-and-management-of-patients-presenting-with-acute-urticaria-or-angioedema Foreign Bodies & Toxic Shock Syndrome Cone LA, Woodard DR, Byrd RG, Schulz K, Kopp SM, Schlievert PM. A recalcitrant, erythematous, desquamating disorder associated with toxin-producing staphylococci in patients with AIDS. J Infect Dis. NIH. PubMed.gov. Published April 1992. Accessed February 11, 2022. https://pubmed.ncbi.nlm.nih.gov/1552193/ Contou D, Colin G, Travert B, et al. Menstrual Toxic Shock Syndrome: A French Nationwide Multicenter Retrospective Study. Clin Infect Dis. Oxford Academic. Published January 15, 2022. Accessed February 11, 2022. https://academic.oup.com/cid/article-abstract/74/2/246/6255963 Parsonnet J, Hansmann MA, Delaney ML, et al. Prevalence of Toxic Shock Syndrome Toxin 1-Producing Staphylococcus aureus and the Presence of Antibodies to This Superantigen in Menstruating Women. J Clin Microbiol. NCBI. Published September 2005. Accessed February 11, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234102/ Shands KN, Schmid GP, Dan BB, et al. Toxic-Shock Syndrome in Menstruating Women: Association with Tampon Use and Staphylococcus aureus and Clinical Features in 52 cases. N Engl J Med. Published December 18, 1980. Accessed February 11, 2022. https://www.nejm.org/doi/full/10.1056/nejm198012183032502?casa_token=GVNPVVA8uB4AAAAA:LQTf1B8PlxwffYbLmuOeWnteCLdkKtwEydZDKn2lYW-NoNe8953D58cgSMnWVnwbN136BWtd23zr Streptococcal Toxic Shock Syndrome: All You Need to Know. Cdc.gov. Published November 23, 2021. Accessed February 11, 2022. https://www.cdc.gov/groupastrep/diseases-public/streptococcal-toxic-shock-syndrome.html Toxic Shock Syndrome (Other Than Streptococcal) (TSS) 2011 case definition. Cdc.gov. Reviewed April 16, 2021. Accessed February 11, 2022. https://ndc.services.cdc.gov/case-definitions/toxic-shock-syndrome-2011/ Foreign Bodies Continued - Management Coskun A, Erkan N, Yakan S, Yıldirim M, Cengiz F. Management of rectal foreign bodies. World J Emerg Surg. Published March 13, 2013. Accessed February 11, 2022. https://wjes.biomedcentral.com/articles/10.1186/1749-7922-8-11 O'Malley G, O'Malley R. Body Packing and Body Stuffing. Merck Manuals Professional Edition. Reviewed/Revised May 2020. Accessed February 11, 2022. https://www.merckmanuals.com/professional/special-subjects/recreational-drugs-and-intoxicants/body-packing-and-body-stuffing Guest Interview: Kenny Walks Across America Facebook. Facebook.com. Accessed February 11, 2022. https://www.facebook.com/KennywalksacrossAmerica Kenny Walks Across America. Kenny Walks Across America. Accessed February 11, 2022. http://www.kennywalksacrossamerica.com Recurring Sources Center for Medical Education. Ccme.org. http://ccme.org The Proceduralist. Theproceduralist.org. http://www.theproceduralist.org The Procedural Pause. Emergency Medicine News. Lww.com. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. Thesgem.com. http://www.thesgem.com Trivia Question: Send answers to 2viewcast@gmail.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to. Be sure to listen in and see what we have to share!
This episode covers tongue conditions, including glossitis, angioedema, candidiasis, geographic tongue, strawberry tongue and black hairy tongue.Written notes can be found at https://zerotofinals.com/surgery/ent/tongueconditions/ or in the ear, nose and throat section of the Zero to Finals surgery book.The audio in the episode was expertly edited by Harry Watchman.